Simba Gill - Chief Executive Officer & President

Prior to founding moksha8, Dr. Gill was an Entrepreneur in Residence and Venture Partner at TPG Growth. He was involved in several of TPG's healthcare investments in the Emerging Markets including ShangPharma and Agria. Prior to joining TPG, Dr. Gill was President of Maxygen and led its IPO in 1999 and raised over $500MM in both public and private financings as well as corporate partnerships. During his tenure at Maxygen, he played a lead role in founding and building three successful spinout companies (Avidia, protein therapeutic company sold to Amgen; Verdia, agri-biotech sold to Dupont and Codexis a novel chemicals company). Dr Gill has previously led Corporate Development activities in a number of biotech companies and formed many significant strategic partnerships with several of the world's major pharmaceutical, agricultural and chemical companies including Roche, Pfizer, AstraZeneca, Novo, Novartis, Lundbeck and DuPont. Earlier in his career, Dr. Gill was Global Marketing Director at Boehringer Mannheim / Roche for the EPO franchise where he helped grow the product to over $1.5BB sales worldwide. Dr Gill also led corporate and market development activities from inception to launch for Roche/Boehringer Mannheim's lead immunodiagnostic platform: the Elecsys system. Dr. Gill began his career in the UK's first biotechnology company, Celltech, as a scientist focused on antibody research and development in the field of cancer research. He earned his PhD in antibody engineering from King's College, London and his MBA from INSEAD in Fontainbleau, France. Dr Gill has lived and worked in eight countries / four continents and speaks five languages.

Alex Howarth - Chief Business Officer

Before joining moksha8, Mr. Howarth was Chief Business Officer at Vitae Pharmaceuticals leading commercial, business development and legal. While at Vitae, Mr. Howarth led the two key strategic alliances with GSK ($175MM) and Boehringer Ingelheim ($336MM) to advance development of its hypertension and diabetes programs. Prior to joining Vitae, Mr. Howarth was Head, Venture Partnerships at GlaxoSmithKline plc (GSK) where he led a team focused on generating value by partnering GSK clinical assets globally. As part of the Worldwide Business Development group, Mr. Howarth executed numerous licensing transactions totaling over $2BB in deal valuations across all phases of development and in a variety of therapeutic areas. Prior to joining GSK, Mr. Howarth worked at KPMG, where he qualified as a chartered accountant. Mr. Howarth received his BSc in Biochemistry from the University of Bath, United Kingdom and conducted molecular biology and neuroscience research at Celltech and Merck. Mr. Howarth has worked in three countries on three continents, speaks two languages.

Dee Athwal - Chief Scientific Officer

Dee Athwal leads the Research and Development activities. Prior to joining moksha8, he was Vice President of Business Development at Celltech-UCB Group from 1998 to 2006 and was involved in the $2.5BB merger between Celltech and UCB. Mr. Athwal is a world-renowned expert in the antibody field responsible for designing every humanized antibody that Celltech has put into clinical development over the past 15 years. During his 25-year tenure at Celltech-UCB Group, he was instrumental in the advancement of the key development programs and in the establishment of some of the biotech / pharmaceutical industry's largest collaborations with organizations such as Amgen, Biogen and Imclone. Mr. Athwal is a visiting lecturer at Kings College, Sheffield University, Oxford University and Nottingham University. He speaks three languages.

Akram Bouchenaki - Senior Vice President, Global Strategic Marketing

Prior to joining moksha8, Dr. Bouchenaki led International Commercial Operations for Gilead Sciences. He joined Gilead in 2000 and helped establish and grow its anti-infectives franchise across more than 40 countries to over $1B under his leadership. In 2006, Truvada, Gilead's new HIV combination product, achieved $ 1.2B in sales representing half of Gilead's overall sales. Before joining Gilead, Dr. Bouchenaki held various senior positions in commercial operations at BMS and GSK and was responsible for marketing multiple blockbusters including Zantac, Zerit and Taxol. Dr. Bouchenaki received his doctorate in pharmacology from the Paris University of Pharmacy. He speaks six languages and has lived and worked in seven different countries on four continents.

Jeannine Medeiros - Vice President, Human Resources and Investor Relations

Prior to joining moksha8, Ms. Medeiros led the investor and public relations department at Maxygen and was actively involved in raising over $300MM in private and public equity financings. She led the branding and corporate positioning of Maxygen from its inception to its highest valuation at a $6BB market capitalization. She also served as head of Human Resources managing growth of the organization in both the US and International headquarters. Ms. Medeiros also ran the West Coast operations of EURO RSCG Life / Noonan Russo representing biotech, pharmaceutical and medical device clients. Ms. Medeiros received her B.A. from Santa Clara University. She has lived and worked in four countries on three continents, speaks three languages.

Philip Ball - Senior Vice President, IT and Project Management

Prior to joining moksha8, Mr. Ball was Vice President of Alliance Consulting with responsibility for over 200 consultants implementing SAP, JDS Edwards and other Enterprise Resource Planning systems. Before this Mr. Ball was President of Morse Consulting a leading consultancy, providing specialist advice to clients in business and IT strategy. Mr. Ball has over 15 years experience in IT consulting, primarily focused on SAP implementation. Prior to his work in the IT industry, Mr. Ball held several senior management positions in Project Management in the Aerospace industry. Mr. Ball has a degree in Aeronautical Engineering and an MSc in Information Systems Strategy from Kingston University.

Peter Tu - Vice President, Legal and Chief IP Counsel

Prior to joining moksha8, Mr. Tu was Senior Director of Intellectual Property at Vitae Pharmaceuticals, Inc., where he was responsible for licensing, patents, trademarks and other legal matters. While at Vitae, Mr. Tu negotiated and drafted numerous licenses and other agreements, including Vitae's $336MM collaboration agreement with Boehringer Ingelheim. Prior to joining Vitae, Mr. Tu served as in-house counsel for various pharmaceutical and biotechnology companies, including Hoffmann-La Roche Inc., Savient Pharmaceuticals, Inc., and Physiome Sciences, Inc. Mr. Tu has received numerous honors and awards, including the Whipple Memorial Scholarship and the National Asian Pacific American Bar Association's "Best Lawyers under 40 in the United States" award in 2002. Mr. Tu earned bachelor's degrees in chemical engineering and biology from MIT, an MBA in finance from Seton Hall University and a JD (magna cum laude) from Seton Hall Law School. Mr. Tu has lived and worked in five countries and three continents.

Akber Pabani - Vice President, Finance

Prior to joining Moksha8, Mr. Pabani was Vice President, Finance at Mars Electronics, the Global Vending and Self Service division of 'M&M' Mars Inc. At Mars Electronics, Mr. Pabani led the global turnaround of the business as the Global Controller and progressed to managing a global business unit. Latterly, Mr. Pabani was the Vice-President - Finance with a focus on M&A activity. Mr. Pabani was a member of the leadership that divested Mars Electronics to Bain Capital in June 2006. Prior to Mars Inc. Mr. Pabani was the Divisional CFO of EDS's pan European Financial Services IT outsourcing business. Mr. Pabani began his career at Eastman Kodak where he was European CFO - Kodak Professional Division. Mr. Pabani is a Chartered Accountant and CPA. He holds an undergraduate degree in Economics from the University of Kent, and received his MBA from London Business School.

Andy Liu - Vice President Global Commercial Operations

Mr. Liu leads Global Commercial Operations. Mr. Liu has over 15 years of commercial operations experience with multi-national pharmaceutical companies. Mr. Liu has worked with Merck and UCB holding several senior management and leadership positions. Mr. Liu’s strength is in P&L management; identifying and executing new business opportunities; and aggressive business turn-around. Mr. Liu has held several operational roles from Business Unit Head to Division Marketing Head to Managing Director/General Manager. During his tenure he has successfully managed and launched products across key therapeutic franchises such as hypertension, atherosclerosis, anticonvulsants, diabetes, arthritis, antihistamine and osteoporosis, including major blockbusters such as Zocor, Vytorin, Cozaar, Hyzaar, Keppra and Fosamax. Mr. Liu also has also led and driven healthcare policy, having represented and led the American Chamber to lobby for pharmaceutical legislation in the areas of pricing, patient access and regulatory approvals. Mr. Liu received his degree from Amherst College. Mr. Liu has lived and worked in fifteen countries on five continents and speaks three languages.

Ayse Kocak - Director General, México

Antes de unirse a moksha8, Ayse Kocak fue Vice Presidente de Mercadotecnia en Cerimon en donde dirigió el desarrollo de estrategias comerciales alrededor de sus líneas de evolución del dolor y autoinmunidad.

Ayse Kocak trabajó en varias posiciones de dirección en Pfizer y sus múltiples subsidiarias alrededor del mundo, incluyendo Europa, Latinoamérica, África y Medio Oriente. En estos mercados dirigió actividades de mercadotecnia y ventas de grandes éxitos en productos medicinales, incluyendo Viagra, Norvasc, Lipitor, Tikosyn y Glucotrol XL. Más recientemente A. Kocak trabajó para Pfizer como Directora de Mercadotecnia del equipo de Anti Psicóticos Pfizer Geodon de Los Estados Unidos. En esta posición, Ayse Kocak supervisó el desarrollo e implementación de las estrategias de negocio para Geodon, un medicamento para el tratamiento de esquizofrenia, así como manías agudas y episodios mixtos asociados con desordenes bipolares. Durante su ocupación, las ventas de Geodon crecieron mas del 30%. Antecediéndo a ésta posición, Ayse participó como Directora de Mercadotecnia para el quipo de Inspra Pfizer, Estados Unidos en donde fue líder del lanzamiento en Los Estados Unidos de Norteamérica de Inspra poara el tratamiento de pacientes que desarrollan cardiopatías consiguientes de ataques cardiacos. Antes de su carrera en Pfizer, Ayse Kocak trabajó como Coordinador de Finanzas en Dogus Holdings en Estambul, Turquía en donde actuó como responsable del manejo de consolidaciones financieras y análisis de las compañías automotrices.

Mario Grieco - EVP & Head of Latin America

Prior to joining moksha8, Dr. Grieco was President, Bristol-Myers Squibb (BMS) Brazil, one of the largest pharma companies in Brazil. During his tenure at BMS, he was implemented a strong turn-around strategy, reorganizing the company and refocusing its marketing efforts. Under his leadership BMS grew by 80% in Brazil. Dr. Grieco also led BMS's government relations strategy in Brazil, working closely on pricing and reimbursement policies. Prior to BMS, Dr. Grieco was Vice President of Latin America for Pharmacia managing over 1,500 employees including three manufacturing sites, growing revenue by 19% to $300MM and earnings by 21%. Prior to working for Pharmacia, Dr. Grieco held a variety of executive positions at GD Searle where he directed Sales and Marketing efforts for Asia Pacific, Latin America and Canada. Dr. Grieco received his M.D. from the Medical School of São Paulo and his M.B.A. from F.S.Camilo, São Paulo, Brazil. He has lived and worked in three countries on two continents, speaks four languages.

We have assembled a world class Board of Directors to help guide the company and contribute to all key aspects of the business. The board is comprised of executives with a deep experience in building global successful companies with international operations and has exceptionally strong connections with Big Pharma and Biotech and across all markets.

Simba Gill, CEO moksha8 & Special Advisor to TPG

Prior to founding moksha8, Dr. Gill was an Entrepreneur in Residence and Venture Partner at TPG Growth. He was involved in several of TPG's healthcare investments in the Emerging Markets including ShangPharma and Agria. Prior to joining TPG, Dr. Gill was President of Maxygen and led its IPO in 1999 and raised over $500MM in both public and private financings as well as corporate partnerships. During his tenure at Maxygen, he played a lead role in founding and building three successful spinout companies (Avidia, protein therapeutic company sold to Amgen; Verdia, agri-biotech sold to Dupont and Codexis a novel chemicals company). Dr Gill has previously led Corporate Development activities in a number of biotech companies and formed many significant strategic partnerships with several of the world's major pharmaceutical, agricultural and chemical companies including Roche, Pfizer, AstraZeneca, Novo, Novartis, Lundbeck, and DuPont. Earlier in his career, Dr. Gill was Global Marketing Director at Boehringer Mannheim / Roche for the EPO franchise where he helped grow the product to over $1.5BB sales worldwide. Dr Gill also led corporate and market development activities from inception to launch for Roche/Boehringer Mannheim's lead immunodiagnostic platform: the Elecsys system. Dr. Gill began his career in the UK's first biotechnology company, Celltech, as a scientist focused on antibody research and development in the field of cancer research. He earned his PhD in antibody engineering from King's College, London and his MBA from INSEAD in Fontainbleau, France. Dr Gill has lived and worked in eight countries/ four continents and speaks five languages.

Geoff Duyk, General Partner, TPG Ventures & Chairman of the Board, moksha8

Prior to joining TPG Growth in 2004, Dr. Duyk served on the Board of Directors and was President of Research & Development at Exelixis where he led a 550+ person group focused on the discovery and development of small molecule therapeutics. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals. Before Millennium, Dr. Duyk was an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute (HHMI). Dr. Duyk has been and continues to be a member of numerous NIH panels and oversight committees focused on the planning and execution of the human genome project. Dr. Duyk holds a Ph.D. and M.D. from Case Western Reserve University and completed his medical and fellowship training at University of California, San Francisco.

Bruce Carter, CEO & Chairman of the Board, Zymogenetics

Dr. Carter has been ZymoGenetics' CEO since 1998 and Chairman of the Board since 2005. Dr. Carter first joined ZymoGenetics in 1986 as Vice President of Research and Development. In 1994, he was chosen as Corporate Executive Vice President and Chief Scientific Officer for Novo Nordisk A/S, the former parent company of ZymoGenetics. He was elected to the board of ZymoGenetics in 1987 and was appointed president in 1998. Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk in 2000. Dr. Carter held various positions of increasing responsibility at G.D. Searle & Co., Ltd. from 1982 to 1986 and was a Lecturer at Trinity College, Dublin from 1975 to 1982. Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.

William L. Meaney, CEO, Zuellig Group

Mr. William L. Meaney is currently the Chief Executive Officer of Zuellig Group, a company with $8B in revenue focused on selling and distributing healthcare products across 12 markets in Asia. Prior to joining Zuellig, Mr. Meaney was the Chief Commercial Officer of Swiss International Airlines. Mr. Meaney has over 20 years' experience in a professional management capacity and a proven track record for successfully building companies in an international career spanning the United States, Africa, Europe and Asia. He has a Bachelor of Science Degree in Mechanical Engineering from Rensselear in Troy, New York and a Master of Business Administration (MBA) degree from Carnegie Mellon University, Pittsburg.

Mohand Sidi-Said, Board Observer/ Advisor to moksha8

Mr. Sidi Said is a former Pfizer Inc. Vice President, and Area President Japan, Asia, Africa, Middle East and Latin America in the Global Pharmaceuticals Division. In addition, he held the positions of Senior Vice President, member of the Executive Leadership Team in the worldwide pharmaceuticals division. He was also a member of the Pfizer Strategy Group, where R&D, Licensing and Development and Acquisitions investment projects were discussed and reviewed. During his years of service with Pfizer, Mr. Sidi Said maintained professional associations with several organizations. He represented Pfizer on the Executive Committee of PhRMA international section and served as the chairman of the PhRMA Japan Steering Committee. Operationally, Mr. Sidi Said was responsible for regions comprising over 50 countries with accountability for several thousand employees and a several billion dollars of revenues. Prior to his role at the New York Headquarters and during his 39 years with Pfizer, he held several operational and leadership positions in many emerging markets.

Davinder Singh Brar, former CEO Ranbaxy Ltd

Mr. Brar served for over 25 years as an executive of Ranbaxy Laboratories Limited, a leading global generics company, rising to Chief Executive Officer and Managing Director. During his tenure, Ranbaxy grew to $1BB in revenue with operations and partnerships outside of India in the United States, Europe and Asia including China. He currently serves as Chairman of GVK Biosciences Private Ltd., a life sciences research company based in India. Mr. Brar was a member of India's Prime Minister's Task Force on Pharmaceuticals and Knowledge-Based Industries, which drafted the blue print for the growth and global expansion of the Indian Pharmaceutical Industry including R&D and Pricing policies.

Barbara Kosacz, Partner, Cooley Godward Kronish LLP & Secretary, moksha8 Board

Barbara is a partner in the business department of Cooley Godward Kronish's Palo Alto office, and the national head of the Firm's Life Sciences practice. Ms. Kosacz has over 15 years of experience in counseling clients in the Life Sciences arena. Her clients range from early-stage start ups to large public companies. Ms. Kosacz advises clients on a variety of legal and business issues. Her particular expertise is in complex strategic partnering and joint venture transactions. She received her BA from Stanford University in 1980, majoring in Classics.

Manish Chapekar, Managing Director Montreux Equity Partners

Mr. Chapekar has 12 years of technical, operating and private equity experience in the life sciences industry. Mr. Chapekar joined Montreux Equity Partners in 2001 and has been a General Partner/Managing Member of Montreux since 2004. Prior to joining Montreux, Mr. Chapekar was a Manager of Strategy and Business Development at Pharmacia (previously Monsanto) responsible for strategic development, in-licensing, acquisitions and investments in life sciences companies and technologies. While at Monsanto, he also worked on several growth and strategic initiatives including developing growth strategies for key products/geographies, accelerating launch of new products, rationalizing the discovery and development processes and developing new business opportunities through the Growth Enterprises Business Incubator.

Mr. Chapekar has received a Bachelor of Technology degree from the Indian Institute of Technology, Bombay; an M.S. in Engineering from the University of Kentucky, where he pursued graduate research in cellular bioengineering, and an M.B.A. from the Stanford University Graduate School of Business. At Stanford, he was founding co-Chairman of the Stanford Global Entrepreneurs' Challenge and co-President of the Stanford GSB Venture Capital Club.